PURPLE BIOTECH LTD.
PPBT · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D49Pre-revenue Israeli oncology biotech with ~$171M accumulated losses and only early/Phase 2 assets dependent on dilutive ATM funding.
Strengths
- CM24 Phase 2 in PDAC showed consistent improvement across efficacy endpoints
- Diversified pipeline (CAPTN-3 platform, CM24, NT219) with a clear FDA pre-IND path
Risks
- History of operating losses and explicit need to raise capital; ATM dilution underway
- Lead programs still preclinical/partnering-dependent; no approved or revenue-generating product
Notable findings
- Cash burnNegative free cash flow (-5.7M)
Key metrics
Return on equity
-274.3%
Return on assets
-150.8%
Current ratio
1.3×
Free cash flow
-$6M
Tangible book value
$10M
Cash & investments
$9M
Cash runway
6q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-19 | 2025-12-31 | 0001213900-26-031365 ↗ |
| 20-F | 2025-03-10 | 2024-12-31 | 0001213900-25-022192 ↗ |
| 20-F | 2024-03-05 | 2023-12-31 | 0001213900-24-020111 ↗ |
| 20-F | 2023-03-03 | 2022-12-31 | 0001213900-23-017024 ↗ |
| 20-F | 2022-03-09 | 2021-12-31 | 0001213900-22-011191 ↗ |
| 20-F | 2021-03-16 | 2020-12-31 | 0001213900-21-015453 ↗ |
| 20-F | 2020-03-23 | 2019-12-31 | 0001213900-20-007156 ↗ |
| 20-F | 2019-03-26 | 2018-12-31 | 0001213900-19-004878 ↗ |
| 20-F | 2018-03-05 | 2017-12-31 | 0001213900-18-002558 ↗ |
| 20-F | 2017-05-01 | 2016-12-31 | 0001213900-17-004462 ↗ |
| 20-F | 2016-03-18 | 2015-12-31 | 0001144204-16-088915 ↗ |